Skip to main content
SpringerLink
Log in
SpringerLink
Log in

TRAIL, Fas Ligand, TNF and TLR3 in Cancer

  • Book
  • © 2017

Overview

Editors:
  1. Olivier Micheau

    1. INSERM, LNC UMR 1231, Dijon, France

    View editor publications

    You can also search for this editor in PubMed   Google Scholar

  • Provides an up-to-date overview of TNF family signal transduction with a special emphasis on TRAIL and Fas L
  • Deals with cell biology, immunology and oncology and in particular drug-resistance mechanisms, as well as prometastatic potential, related to the cell biology of the downstream signaling components of the TNF superfamily
  • Addresses how post-translational modifications of TNF related members or their cleavage by proteases affect their signaling capacity
  • Includes supplementary material: sn.pub/extras

Part of the book series: Resistance to Targeted Anti-Cancer Therapeutics (RTACT, volume 12)

This is a preview of subscription content, log in via an institution to check access.

Access this book

Log in via an institution
eBook USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Other ways to access

Licence this eBook for your library

Institutional subscriptions

Table of contents (12 chapters)

  1. Front Matter

    Pages i-xiii
    Download chapter PDF

  2. Resistance to TRAIL Pathway-Targeted Therapeutics in Cancer

    • Jessica Wagner, Christina Leah Kline, Wafik El-Deiry
    Pages 1-25

  3. TRAIL-R3/R4 and Inhibition of TRAIL Signalling in Cancer

    • Lubna Danish, Daniela Stöhr, Peter Scheurich, Nadine Pollak
    Pages 27-57

  4. IAPs and Resistance to Death Receptors in Cancer

    • Laurence Dubrez, Simone Fulda
    Pages 59-77

  5. Bcl-2 Proteins and TRAIL Resistance in Melanoma

    • Jürgen Eberle
    Pages 79-90

  6. Regulation of Caspase-Mediated Apoptosis by the Tumor Suppressor Par-4

    • James Sledziona, Vivek M. Rangnekar
    Pages 91-106

  7. Stem Cell Regulation by Death Ligands and Their Use in Cell Therapy

    • Andrea Mohr, Ralf Zwacka
    Pages 107-129

  8. Atypical Immune Functions of CD95/CD95L

    • Amanda Poissonnier, Patrick Legembre
    Pages 131-157

  9. TLR3 Is a Death Receptor Target in Cancer Therapy

    • Yann Estornes, Toufic Renno, Serge Lebecque
    Pages 159-185

  10. Fas/CD95, Lipid Rafts, and Cancer

    • Faustino Mollinedo, Consuelo Gajate
    Pages 187-227

  11. Role of Sphingolipids in Death Receptor Signalling

    • Fatima Bilal, Michaël Pérès, Nathalie Andrieu-Abadie, Thierry Levade, Bassam Badran, Ahmad Daher et al.
    Pages 229-245

  12. Posttranslational Modifications and Death Receptor Signalling

    • Olivier Micheau
    Pages 247-290

  13. System Modeling of Receptor-Induced Apoptosis

    • François Bertaux, Dirk Drasdo, Grégory Batt
    Pages 291-307

  14. Back Matter

    Pages 309-317
    Download chapter PDF
Back to top

Keywords

About this book

This volume provides the current understanding of death receptor's/TLR3 signaling regulation in cancer. Death receptors, including TRAIL-R1, TRAIL-R2, Fas and TNF-RI, owing to their ability to trigger apoptosis and to contribute to the elimination of cancer cells by the immune system have been considered, to variable extent, as important therapeutic targets for cancer therapy. But an increasing body of evidence suggests that some of these receptors may also contribute to tumorigenesis, or that new players such as TLR3 may be targeted for cancer therapy due to their ability to behave like death receptors.

Editors and Affiliations

  • INSERM, LNC UMR 1231, Dijon, France

    Olivier Micheau

About the editor

Dr. Olivier Micheau is a research director of the INSERM (French National Institute of Health), UMR1231. He received his PhD in  Biochemistry and Molecular and Cellular Biology in 1999 from the University of Burgundy, France. He next moved as a post-doctoral fellow in Jurg Tschopp’s laboratory in Epalinges, Switzerland, from 1999 to 2003, where he elucidated the molecular mechanisms underlying TNFR1’s dual signaling ability. He described for the first time TNFR1 cytosolic pro-apoptotic complex II. In 2003 he joined the INSERM unit U517 headed by Professor E. Solary in Dijon, France, as an INSERM researcher. Member of several scientific councils, including INSERM CSS3 (2012-2016) and Fondation ARC pour la recherche sur le cancer, a French Charity (since 2015), he is also Associate Editor of the British Journal of Pharmacology since 2012. His scientific interest focuses on TRAIL receptor signaling and its use in cancer therapy.

Bibliographic Information

  • Book Title: TRAIL, Fas Ligand, TNF and TLR3 in Cancer

  • Editors: Olivier Micheau

  • Series Title: Resistance to Targeted Anti-Cancer Therapeutics

  • DOI: https://doi.org/10.1007/978-3-319-56805-8

  • Publisher: Springer Cham

  • eBook Packages: Biomedical and Life Sciences, Biomedical and Life Sciences (R0)

  • Copyright Information: Springer International Publishing AG 2017

  • Hardcover ISBN: 978-3-319-56804-1Published: 10 July 2017

  • Softcover ISBN: 978-3-319-86006-0Published: 12 August 2018

  • eBook ISBN: 978-3-319-56805-8Published: 03 July 2017

  • Series ISSN: 2196-5501

  • Series E-ISSN: 2196-551X

  • Edition Number: 1

  • Number of Pages: XIII, 317

  • Number of Illustrations: 5 b/w illustrations, 35 illustrations in colour

  • Topics: Cancer Research

Publish with us

Policies and ethics

Back to top

Search

Navigation